The SEIZURE Score Faces Global Challenges: International Validation Highlights Geographic Disparities in Predicting Encephalitis Seizures
Posted inInfectious Diseases Neurology news

The SEIZURE Score Faces Global Challenges: International Validation Highlights Geographic Disparities in Predicting Encephalitis Seizures

An international evaluation of the SEIZURE score reveals limited global predictive power for acute seizures in encephalitis. While the tool performs well in Western Europe, particularly Portugal, its utility elsewhere is hampered by etiological diversity and diagnostic limitations.
Precision Base-Editing and Universal CAR7 T Cells: Transforming the Treatment Landscape for Refractory T-Cell Acute Lymphoblastic Leukemia
Posted inHematology-Oncology news Oncology

Precision Base-Editing and Universal CAR7 T Cells: Transforming the Treatment Landscape for Refractory T-Cell Acute Lymphoblastic Leukemia

Recent clinical trials demonstrate the rapid evolution of CD7-targeted CAR T-cell therapies. From donor-derived models to universal base-edited cells, these innovations offer high remission rates and a viable bridge to transplant for patients with relapsed T-cell acute lymphoblastic leukemia.
Short-Course Ianalumab Combined with Eltrombopag: A Potential Shift Toward Sustained Remission in Immune Thrombocytopenia
Posted inHematology-Oncology Internal Medicine news

Short-Course Ianalumab Combined with Eltrombopag: A Potential Shift Toward Sustained Remission in Immune Thrombocytopenia

The VAYHIT2 Phase 3 trial demonstrates that adding the BAFF-R monoclonal antibody ianalumab to eltrombopag significantly extends treatment-free intervals and improves stable response rates in patients with relapsed or refractory immune thrombocytopenia (ITP) compared to eltrombopag alone.
Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention
Posted inHematology-Oncology news Oncology

Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention

The phase 3 MajesTEC-3 trial demonstrates that combining teclistamab with daratumumab significantly extends progression-free survival compared to standard therapies in patients with relapsed or refractory multiple myeloma, achieving high rates of complete response and minimal residual disease negativity.
Ketamine vs. Etomidate: Does Your Choice of Induction Agent Influence Mortality in the Critically Ill?
Posted inAnesthesiology Critical Care news

Ketamine vs. Etomidate: Does Your Choice of Induction Agent Influence Mortality in the Critically Ill?

This article explores recent evidence comparing ketamine and etomidate for rapid sequence intubation. While new cohort data suggests a mortality benefit for ketamine, meta-analyses of randomized trials show clinical equipoise, highlighting the complex trade-offs between adrenal suppression and hemodynamic stability.
Trastuzumab Deruxtecan Redefines Postneoadjuvant Care for High-Risk HER2-Positive Early Breast Cancer: Insights from DESTINY-Breast05
Posted innews Oncology

Trastuzumab Deruxtecan Redefines Postneoadjuvant Care for High-Risk HER2-Positive Early Breast Cancer: Insights from DESTINY-Breast05

The DESTINY-Breast05 trial demonstrates that Trastuzumab Deruxtecan significantly improves invasive disease-free survival compared to Trastuzumab Emtansine in patients with residual HER2-positive early breast cancer, establishing a new potential standard of care while highlighting the need for vigilant monitoring of interstitial lung disease.
High-Dose Influenza Vaccine Fails to Significantly Reduce Combined Influenza and Pneumonia Hospitalizations: Insights from the DANFLU-2 Trial
Posted inInfectious Diseases news Public Health Respiratory

High-Dose Influenza Vaccine Fails to Significantly Reduce Combined Influenza and Pneumonia Hospitalizations: Insights from the DANFLU-2 Trial

The DANFLU-2 trial found that while high-dose influenza vaccines significantly reduced influenza-specific hospitalizations in older adults, they did not reach statistical significance for the combined primary endpoint of influenza or pneumonia hospitalizations compared to standard-dose vaccines.
Tirzepatide Achieves Cardiovascular Noninferiority Against Dulaglutide: A Milestone in Dual Incretin Therapy
Posted inCardiology Diabetes & Endocrinology news

Tirzepatide Achieves Cardiovascular Noninferiority Against Dulaglutide: A Milestone in Dual Incretin Therapy

The SURPASS-CVOT trial confirms that tirzepatide is noninferior to dulaglutide for cardiovascular safety in high-risk type 2 diabetes patients. While superiority was not statistically reached, the study solidifies the cardiovascular profile of dual GIP/GLP-1 agonism compared to established standards of care.
High-Dose Oral Rifampin Did Not Improve Survival in Tuberculous Meningitis—HARVEST Trial Shows No Benefit and Possible Harm
Posted inInfectious Diseases Neurology news

High-Dose Oral Rifampin Did Not Improve Survival in Tuberculous Meningitis—HARVEST Trial Shows No Benefit and Possible Harm

A multinational randomized trial found that adding high‑dose oral rifampin (total 35 mg/kg for 8 weeks) to standard therapy did not reduce 6‑month mortality in adults with tuberculous meningitis and was associated with more drug‑induced liver injury and earlier deaths in some patients.
Validated PRESEV Score Identifies Adults with Sickle Cell VOC at Low Risk for Acute Chest Syndrome — Implications for Safer Outpatient Management
Posted inHematology-Oncology news

Validated PRESEV Score Identifies Adults with Sickle Cell VOC at Low Risk for Acute Chest Syndrome — Implications for Safer Outpatient Management

An international prospective validation confirms the PRESEV score reliably identifies adult sickle cell patients hospitalized for vaso-occlusive crisis (VOC) who are at low risk for acute chest syndrome (ACS), enabling safer outpatient management strategies in selected patients.
High-frequency Oscillatory Ventilation in Near‑Term and Term Infants: Inconclusive Benefit and Possible Increased Mortality — What the 2025 Cochrane Update Tells Clinicians
Posted innews Pediatrics Respiratory

High-frequency Oscillatory Ventilation in Near‑Term and Term Infants: Inconclusive Benefit and Possible Increased Mortality — What the 2025 Cochrane Update Tells Clinicians

A 2025 Cochrane update (3 RCTs, 368 infants) finds very low- to low-certainty evidence that HFOV neither clearly reduces treatment failure nor pulmonary air leak and may increase mortality versus conventional ventilation in term/near‑term infants with severe pulmonary dysfunction.